Osimertinib: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='99/999451/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='99/999451/Cv/1'> | ||
Osimertinib, sold under the brand name Tagrisso,<ref name="a4">[https://www.who.int/medicines/publications/druginformation/INN_List113.pdf "Proposed INN: List 113"] (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015</ref> is a medication used to treat non-small-cell lung carcinomas with specific mutations.<ref name="a5">PMID:26169963</ref><ref name="a6">PMID:26370354</ref> It is a third-generation [[epidermal growth factor receptor]] [[tyrosine | Osimertinib, sold under the brand name Tagrisso,<ref name="a4">[https://www.who.int/medicines/publications/druginformation/INN_List113.pdf "Proposed INN: List 113"] (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015</ref> is a medication used to treat non-small-cell lung carcinomas with specific mutations.<ref name="a5">PMID:26169963</ref><ref name="a6">PMID:26370354</ref> It is a third-generation [[epidermal growth factor receptor]] tyrosine kinase inhibitor (see [[Receptor tyrosine kinases]]). See also [https://en.wikipedia.org/wiki/Osimertinib Osimertinib]. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||